Schedule 33A Transitional provision in relation to EU ExitF1
- 1Interpretation
- 2Manufacturing, wholesale dealing and brokering
- 3Transitional provision in respect of conversion of EU marketing authorisations in force immediately before IP completion day
- 4Transitional provision in respect of UK marketing authorisations, parallel import licences and parallel distribution notices
- 5Transitional provision in relation to variations of marketing authorisations other than converted EU marketing authorisations
- 6Transitional provision in relation to the Paediatric Regulation
- 8Transitional provision in respect of homoeopathic medicinal products
- 9Transitional provision in respect of traditional herbal registrations
- 10Transitional provision in respect of pharmacovigilance
- 11Transitional provision in respect of Part 12
- 12General provision in relation to transitional provisions
Annotations
Textual amendments
- F1
Sch. 33A inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 7 (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 193); 2020 c. 1, Sch. 5 para. 1(1)